Please provide your email address to receive an email when new articles are posted on . Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely ...

Ankylosing spondylitis is a type of arthritis that inflames joints of the spine and leaves your back stiff and painful. If nonsteroidal anti-inflammatory drugs (NSAIDs) aren't enough to relieve your ...

How long do you need to take a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis before it's fully effective? It depends on which one you use. But they all take a while, says Eric ...

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Therapeutic drug monitoring (TDM) — the practice of using laboratory testing to measure blood levels of drugs — has garnered growing interest among rheumatologists in managing patients on ...

Please provide your email address to receive an email when new articles are posted on . Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted ...

Racial-ethnic disparities in care quantity and quality have been well documented throughout medicine. This study focused on rheumatoid arthritis patients' use of disease-modifying anti-rheumatic drugs ...

Patients with rheumatoid arthritis (RA) in a large Swedish population cohort show a reduced incidence of autoimmune thyroid diseases, such as hypothyroidism or hyperthyroidism, after being diagnosed ...

Nonadherence to DMARDs in RA varies widely, with rates from 1.5% to 100% across different studies and DMARD classes. The review identified 31 unique nonadherence measures, with indirect methods like ...